AI-generated research brief — verify at source
OLE-Potassium Supplement Reduces Morning Systolic BP and Improves Lipid Profile in Mild Hypertension
In adults with untreated mild to moderate hypertension, 12 weeks of daily olive leaf extract combined with potassium reduced morning systolic blood pressure by 5.4 mmHg on home monitoring, alongside reductions in total cholesterol by 11.1 mg/dL, LDL-cholesterol by 6.9 mg/dL, triglycerides by approximately 22 mg/dL, and oxidized LDL by roughly 23% compared to placebo. These findings suggest the combination may offer broad cardiometabolic benefit beyond blood pressure control alone, though the small trial size warrants caution in interpretation.
What Was Studied
The trial investigated whether a fixed daily combination of olive leaf extract (OLE) and potassium could meaningfully reduce blood pressure and improve key cardiometabolic markers in adults with untreated mildly to moderately elevated blood pressure. Secondary outcomes included lipid levels, glycaemic and insulin measures, oxidative stress markers, and quality of life, given that hypertension in this population frequently co-occurs with dyslipidemia and insulin resistance within the metabolic syndrome.
How It Was Studied
This was a randomized, double-blind, placebo-controlled trial enrolling 70 adults with untreated mild to moderate hypertension. Participants were assigned to receive either an active supplement — providing 1000 mg of olive leaf extract (standardised to at least 160 mg oleuropein) plus 300 mg of potassium per day — or a matched placebo over 12 weeks. Blood pressure was captured through both standard office measurements and 7-day home-based monitoring, with the latter providing a more ecologically valid reading of habitual blood pressure levels. Cardiometabolic markers including lipid fractions, fasting glucose, insulin, HbA1c, and oxidized LDL were assessed at scheduled timepoints during the intervention.
What Was Observed
- Blood pressure response favoured the active group on home monitoring: Office blood pressure fell significantly over time in both groups, indicating a possible placebo or measurement effect. However, 7-day home-based monitoring revealed a meaningfully greater reduction in morning systolic blood pressure in the supplement group, with a decrease of 5.4 mmHg compared to placebo — a difference considered clinically relevant at this range of baseline elevation.
- Lipid profile improved significantly by mid-intervention: At Week 6, total cholesterol fell by 11.1 mg/dL, LDL-cholesterol by 6.9 mg/dL, and triglycerides by approximately 22 mg/dL in the verum group relative to placebo. HDL-cholesterol remained stable, suggesting the lipid improvements were not offset by reductions in the protective fraction.
- Oxidative stress marker declined substantially: Oxidized LDL — a marker of lipid peroxidation and vascular oxidative stress — decreased by approximately 23% in the supplement group, without corresponding changes in high-sensitivity C-reactive protein (hs-CRP), indicating selective improvement in oxidative rather than inflammatory pathways.
- Insulin sensitivity showed modest improvement: Fasting glucose and HbA1c were unchanged across groups, but fasting insulin levels and the HOMA-Index — a composite estimate of insulin resistance — declined in the verum group, pointing to a modest enhancement of insulin sensitivity independent of glycaemic control.
Why This Matters
Hypertension in the context of metabolic syndrome is rarely an isolated finding; it typically clusters with dyslipidemia and insulin resistance, raising overall cardiovascular risk beyond what blood pressure elevation alone would predict. This study suggests that an OLE-potassium combination may simultaneously address several of these interconnected risk factors, which could be relevant for individuals who are untreated or not yet candidates for pharmacotherapy. The observed effects on oxidized LDL and insulin sensitivity also implicate mechanistic pathways — oxidative stress and metabolic dysregulation — that go beyond conventional antihypertensive targets.
How to Read This Result
While the direction of findings is consistently positive across multiple cardiometabolic outcomes, the small sample size of 70 participants and the 12-week duration limit the confidence with which these results can be generalised or extrapolated to longer-term cardiovascular outcomes.
Limitations
The abstract does not explicitly report study limitations.